Atreca Inc at Stifel Healthcare Conference Transcript
(technical difficulty) of the in-person Stifel Healthcare Conference. Glad to have with us here, to start things off this morning, Atreca. We have the Chief Executive Officer, John Orwin. We have the Chief Strategy Officer, Tito Serafini; and the new Chief Scientific Officer, Stephen Gould.
I don't know, John, if you want to make any opening comments at all before we get into Q&A. Or do you want to --?
Sure. I mean, maybe I'll just -- for people who aren't familiar with the company -- just comment briefly on who we are and what we do. We discover antibody target pairs by interrogating human immune responses, specifically looking at a subset of B cells that emerge in the presence of infectious disease or -- which is kind of where the company had its roots -- and in cancer patients. And by sequencing those plasmablasts, we identify antibodies that are binding to novel tumor antigens that are shared tumor antigens. And this platform is something that we've been investing in now for, I guess, 10
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
